Autism spectrum disorders are a heterogeneous group of behaviorally defined disorders having complex etiologies. We previously reported a direct correlation between lower plasma levels of the immunoglobulins (Ig) IgG and IgM and increased severity of behavioral symptoms in children with autism. Our current objective was to determine if these reduced plasma levels of IgG and IgM are the result of defective B cell development, activation, or function. Results suggest no differences in the B cell parameters measured, indicating that decreased Ig in autism is not a result of B cell dysfunction and other immune cells might be involved.
Introduction
Autism spectrum disorders (ASD) are a heterogeneous group of behaviorally defined disorders that are widely considered to be genetic in origin on account of the high rates of heritability. However, only a minority of ASD cases have been directly associated with a genetic change including chromosomal abnormalities, copy number variations (CNV), and single-gene disorders (Miles, 2011) . Moreover, the etiological significance of these changes has yet to be fully determined. It is likely that the risk associated with genetic perturbations is manifested by either a direct impact on the nervous system, or indirectly through the disruption of peripheral organ systems that negatively affect nervous system development and/or function. The immune system is one such network that has been shown to be very important during neurodevelopment as well as in adult brain homeostasis (Mehler and Kessler, 1998; Marques-Deak et al., 2005) , and perturbations of which have been linked to autism.
Previous studies have reported changes in several aspects of the immune system in children with autism. These include differences in immune cell numbers, differences in immune cell phenotype, the presence of autoantibodies, altered cytokine profiles, immune pathology in the gut, altered levels of complement proteins, and altered levels of immunoglobulins (Ashwood et al., 2006) . Of these immune differences, changes in levels of immunoglobulins are commonly reported. However, these reports are often variable and no clear consensus has emerged. For example, IgG and IgM have been reported to be both increased (Croonenberghs et al., 2002; Trajkovski et al., 2004) and decreased (Gupta et al., 1996; Ashwood et al., 2003) in children with ASD compared to typically developing controls. Differences that are most likely attributed to small sample sizes (range 18-40 autism subjects), variations in types of controls (siblings vs. age-matched general population controls), associated medical conditions (such as gastrointestinal dysfunction), age, and method of detection. Previously, our laboratory conducted a large study including 143 children with an autism spectrum disorder aged 2-5 years as well as 96 aged matched general population controls and 32 aged matched developmentally delayed controls. We reported lower levels of immunoglobulin (IgG and IgM) in children with autism, which significantly correlated with severity of behavioral symptoms (Heuer et al., 2008) . Following this publication, a study of the same population of children reported an increase in IgG4, a subclass of IgG, but no change in the remaining subclasses IgG1, IgG2, and IgG3 using a different method of detection (Enstrom et al., 2009 ), adding to the uncertainty of immunoglobulin production as a predictor of autism risk.
Immunoglobulin production is the end result of B cell activation, and is generated during an immune response. We hypothesized that the altered levels of total immunoglobulin were indicative of a defect in cellular function within the B cell fraction, and that the discovery of 
